Quiz|Articles|July 21, 2024

Targeted Pulse Quiz: July 21

Author(s)Morgan Bayer

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Ready for the challenge? Let’s begin!

Which combination therapy showed superior progression-free survival compared with osimertinib for EGFR-mutated NSCLC?


Related to this article

FDA Removes PCNSL Limitation From Liso-Cel Label
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.